A little boy from Cheam has been diagnosed with a condition so rare that, since its discovery in 1965, fewer than 25 cases have been recorded worldwide. Alfie Mumford, four, suffers from the complex Gillespie syndrome, characterised by partial aniridia, meaning that part of his iris is missing and his...
Latest News
Tempe, Arizona – Cell death is fundamental to life and, thus, healthy aging. In the realm of cellular biology, ferroptosis (a form of programmed cell death) has emerged not only as a focal point of research for its potential in eliminating cancer cells, but also its role in a plethora...
MELBOURNE, Australia, and MENLO PARK, California U.S.A. – ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentation and discussion today at the 2009 American Society of Clinical Oncology...
SAN CARLOS, Calif. – ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or...
Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude Children’s Research Hospital clinical trial that included a novel monoclonal antibody produced onsite. The findings appeared today in the Journal of Clinical Oncology. Neuroblastoma is a cancer of immature nerve cells in the sympathetic nervous system. The tumor...
TEL AVIV, Israel — Chemomab Therapeutics Ltd., a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis (PSC)....
First U.S. IND Enables Increase in the Number of Clinical Sites for Chemomab’s Ongoing Phase 2 SPRING Trial Initiation of U.S. Trials in Line with Announced Corporate Strategy to Expand the Company’s Clinical and Commercial Presence in the U.S. TEL AVIV, Israel – Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a...
TEL AVIV, Israel — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced publication of proteomic analyses that further demonstrate the unique role of the soluble protein CCL24 in driving pathologies associated with...
TEL AVIV, Israel — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease...
According to the results of a phase 3 study published in Blood Advances, the antisense oligonucleotide (ASO) oblimersen can be added safely to conventional chemotherapy for older patients with acute myeloid leukemia (AML), and although adding the ASO did not improve complete remission (CR) rates, it appeared to improve disease-free survival...